System Delay and Clinical Outcome Among Chinese Patients With AMI Treated With Reperfusion Therapy (MOODY Study)
System Delay and Clinical Outcome Among Chinese Patients With AMI Treated With Reperfusion Therapy (MOODY Study)
Acute myocardial infarction (AMI) pose a pool clinical outcome to men and women whom
 treatment was delayed. However, reperfusion time was limited in previous studies. To evaluate
 the system delay and clinical outcomes among Chinese patients with AMI, consecutive inpatient
 case prospectively collected from 1999 to 2016. Basic data and innovative evidence will
 accelerate evidence-based clinical practice and policy making, and improve AMI patients
 outcomes finally.
AMI is one of the leading causes of mortality and morbidity in public health globally, as
 well as in China. Remarkable variations of repercussion time and clinical outcome have been
 noted, however little information is available about how shortened D2B time is incorporated
 appropriately into routine clinical practice in China. In addition, basic data and evidence
 about effectiveness of treatment for AMI during long-term recovery is limited. Practical and
 applied knowledge from large unselected population is needed to guide practice for
 improvement.

 This study will enroll patients with a confirmed diagnosis of AMI consecutively in China. At
 study entry, participants will be interviewed during their index hospitalization, to collect
 information about symptoms, functioning, quality of life, and medical care. Demographic
 characteristics, medical history, clinical features, diagnostic tests, medications,
 procedures, and in-hospital outcomes of patients will be abstracted from medical records by
 well trained professional abstractors. At 1 month, and 12 month after discharge, participants
 will return to the clinic for follow up visits. This study will examine system delay that may
 affect patients recovery after a heart attack. Effective clinic path system, and risk model
 for AMI patients will be established based on the findings, to improve patients outcomes in
 future finally.
Inclusion Criteria:

 -  Hospitalized patients with acute myocardial infarction according to positive cardiac
 biomarkers (Troponin I/T, CK-MB or CK≥ local laboratory upper limit of normal values
 within 24 hours after initial presentation, and at least one of the following two
 supporting evidence of ischemia (ischemic symptoms occurring within 24 hours before
 admission or up to 72 hours for STEMI; ECG changes indicative of new ischemia).

 Exclusion Criteria:

 -  Previously enrolled in the similar study